Clinical trial analysis of 2019‐nCoV therapy registered in China
So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and o...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 2020-06, Vol.92 (6), p.540-545 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 545 |
|---|---|
| container_issue | 6 |
| container_start_page | 540 |
| container_title | Journal of medical virology |
| container_volume | 92 |
| creator | Zhang, Qi Wang, Yakun Qi, Changsong Shen, Lin Li, Jian |
| description | So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period. |
| doi_str_mv | 10.1002/jmv.25733 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7228274</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2391283955</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4713-494cf291b8abbe70012e1a5df16df3d2c68f790736030150fa399df4f6da0e653</originalsourceid><addsrcrecordid>eNp1kL9OwzAQhy0EoqUw8AIoEhND2rOdOPGCBBF_VcQCXS0nsVtXaVLstCgbj8Az8iSkpCAYWO6G-_Td3Q-hYwxDDEBG88V6SMKI0h3Ux8CZzyHCu6gPOGA-YzjsoQPn5gAQc0L2UY8SDDENSR9dJoUpTSYLr7amrbKUReOM8yrtEcD84-29TKqJV8-UlcvGs2pqXK2syj1TesnMlPIQ7WlZOHW07QP0fH31lNz648ebu-Ri7GdBhKkf8CDThOM0lmmqIgBMFJZhrjHLNc1JxmIdtYdTBhRwCFpSznMdaJZLUCykA3TeeZerdKHyTJW1lYVYWrOQthGVNOLvpDQzMa3WIiIkJlHQCk63Alu9rJSrxbxa2fZhJwjlmMSUh5s1Zx2V2co5q_TPBgxiE7do4xZfcbfsye-TfsjvfFtg1AGvplDN_yZx_zDplJ8lk4nN</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2391283955</pqid></control><display><type>article</type><title>Clinical trial analysis of 2019‐nCoV therapy registered in China</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><creator>Zhang, Qi ; Wang, Yakun ; Qi, Changsong ; Shen, Lin ; Li, Jian</creator><creatorcontrib>Zhang, Qi ; Wang, Yakun ; Qi, Changsong ; Shen, Lin ; Li, Jian</creatorcontrib><description>So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.25733</identifier><identifier>PMID: 32108352</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adenosine Monophosphate - analogs & derivatives ; Adenosine Monophosphate - therapeutic use ; Alanine - analogs & derivatives ; Alanine - therapeutic use ; Amides - therapeutic use ; Antiviral agents ; Antiviral Agents - therapeutic use ; Betacoronavirus - drug effects ; Betacoronavirus - genetics ; Betacoronavirus - pathogenicity ; China ; China - epidemiology ; Chloroquine - analogs & derivatives ; Chloroquine - therapeutic use ; clinical trial ; Clinical trials ; Clinical Trials as Topic ; Coronaviridae ; Coronavirus Infections - diagnosis ; Coronavirus Infections - drug therapy ; Coronavirus Infections - epidemiology ; Coronavirus Infections - virology ; Coronaviruses ; COVID-19 ; Disease Management ; Disease Outbreaks ; Drugs ; Drugs, Chinese Herbal - therapeutic use ; Glucocorticoids ; Herbal medicine ; Humans ; Medicine, Chinese Traditional - methods ; new coronavirus pneumonia ; new drugs ; Nucleic acids ; Pandemics ; Pneumonia, Viral - diagnosis ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - epidemiology ; Pneumonia, Viral - virology ; Practice Guidelines as Topic ; Pyrazines - therapeutic use ; SARS-CoV-2 ; Vaccines ; Viral diseases ; Virology ; Viruses</subject><ispartof>Journal of medical virology, 2020-06, Vol.92 (6), p.540-545</ispartof><rights>2020 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4713-494cf291b8abbe70012e1a5df16df3d2c68f790736030150fa399df4f6da0e653</citedby><cites>FETCH-LOGICAL-c4713-494cf291b8abbe70012e1a5df16df3d2c68f790736030150fa399df4f6da0e653</cites><orcidid>0000-0002-9333-3255 ; 0000-0001-5579-2998 ; 0000-0002-8144-3609</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.25733$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.25733$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32108352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Qi</creatorcontrib><creatorcontrib>Wang, Yakun</creatorcontrib><creatorcontrib>Qi, Changsong</creatorcontrib><creatorcontrib>Shen, Lin</creatorcontrib><creatorcontrib>Li, Jian</creatorcontrib><title>Clinical trial analysis of 2019‐nCoV therapy registered in China</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description>So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period.</description><subject>Adenosine Monophosphate - analogs & derivatives</subject><subject>Adenosine Monophosphate - therapeutic use</subject><subject>Alanine - analogs & derivatives</subject><subject>Alanine - therapeutic use</subject><subject>Amides - therapeutic use</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Betacoronavirus - drug effects</subject><subject>Betacoronavirus - genetics</subject><subject>Betacoronavirus - pathogenicity</subject><subject>China</subject><subject>China - epidemiology</subject><subject>Chloroquine - analogs & derivatives</subject><subject>Chloroquine - therapeutic use</subject><subject>clinical trial</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Coronaviridae</subject><subject>Coronavirus Infections - diagnosis</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Coronavirus Infections - virology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Disease Management</subject><subject>Disease Outbreaks</subject><subject>Drugs</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Glucocorticoids</subject><subject>Herbal medicine</subject><subject>Humans</subject><subject>Medicine, Chinese Traditional - methods</subject><subject>new coronavirus pneumonia</subject><subject>new drugs</subject><subject>Nucleic acids</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - diagnosis</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Pneumonia, Viral - virology</subject><subject>Practice Guidelines as Topic</subject><subject>Pyrazines - therapeutic use</subject><subject>SARS-CoV-2</subject><subject>Vaccines</subject><subject>Viral diseases</subject><subject>Virology</subject><subject>Viruses</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kL9OwzAQhy0EoqUw8AIoEhND2rOdOPGCBBF_VcQCXS0nsVtXaVLstCgbj8Az8iSkpCAYWO6G-_Td3Q-hYwxDDEBG88V6SMKI0h3Ux8CZzyHCu6gPOGA-YzjsoQPn5gAQc0L2UY8SDDENSR9dJoUpTSYLr7amrbKUReOM8yrtEcD84-29TKqJV8-UlcvGs2pqXK2syj1TesnMlPIQ7WlZOHW07QP0fH31lNz648ebu-Ri7GdBhKkf8CDThOM0lmmqIgBMFJZhrjHLNc1JxmIdtYdTBhRwCFpSznMdaJZLUCykA3TeeZerdKHyTJW1lYVYWrOQthGVNOLvpDQzMa3WIiIkJlHQCk63Alu9rJSrxbxa2fZhJwjlmMSUh5s1Zx2V2co5q_TPBgxiE7do4xZfcbfsye-TfsjvfFtg1AGvplDN_yZx_zDplJ8lk4nN</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Zhang, Qi</creator><creator>Wang, Yakun</creator><creator>Qi, Changsong</creator><creator>Shen, Lin</creator><creator>Li, Jian</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9333-3255</orcidid><orcidid>https://orcid.org/0000-0001-5579-2998</orcidid><orcidid>https://orcid.org/0000-0002-8144-3609</orcidid></search><sort><creationdate>202006</creationdate><title>Clinical trial analysis of 2019‐nCoV therapy registered in China</title><author>Zhang, Qi ; Wang, Yakun ; Qi, Changsong ; Shen, Lin ; Li, Jian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4713-494cf291b8abbe70012e1a5df16df3d2c68f790736030150fa399df4f6da0e653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adenosine Monophosphate - analogs & derivatives</topic><topic>Adenosine Monophosphate - therapeutic use</topic><topic>Alanine - analogs & derivatives</topic><topic>Alanine - therapeutic use</topic><topic>Amides - therapeutic use</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Betacoronavirus - drug effects</topic><topic>Betacoronavirus - genetics</topic><topic>Betacoronavirus - pathogenicity</topic><topic>China</topic><topic>China - epidemiology</topic><topic>Chloroquine - analogs & derivatives</topic><topic>Chloroquine - therapeutic use</topic><topic>clinical trial</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Coronaviridae</topic><topic>Coronavirus Infections - diagnosis</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Coronavirus Infections - virology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Disease Management</topic><topic>Disease Outbreaks</topic><topic>Drugs</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Glucocorticoids</topic><topic>Herbal medicine</topic><topic>Humans</topic><topic>Medicine, Chinese Traditional - methods</topic><topic>new coronavirus pneumonia</topic><topic>new drugs</topic><topic>Nucleic acids</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - diagnosis</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Pneumonia, Viral - virology</topic><topic>Practice Guidelines as Topic</topic><topic>Pyrazines - therapeutic use</topic><topic>SARS-CoV-2</topic><topic>Vaccines</topic><topic>Viral diseases</topic><topic>Virology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Qi</creatorcontrib><creatorcontrib>Wang, Yakun</creatorcontrib><creatorcontrib>Qi, Changsong</creatorcontrib><creatorcontrib>Shen, Lin</creatorcontrib><creatorcontrib>Li, Jian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Qi</au><au>Wang, Yakun</au><au>Qi, Changsong</au><au>Shen, Lin</au><au>Li, Jian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical trial analysis of 2019‐nCoV therapy registered in China</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2020-06</date><risdate>2020</risdate><volume>92</volume><issue>6</issue><spage>540</spage><epage>545</epage><pages>540-545</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32108352</pmid><doi>10.1002/jmv.25733</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-9333-3255</orcidid><orcidid>https://orcid.org/0000-0001-5579-2998</orcidid><orcidid>https://orcid.org/0000-0002-8144-3609</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2020-06, Vol.92 (6), p.540-545 |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7228274 |
| source | Wiley-Blackwell Journals; MEDLINE |
| subjects | Adenosine Monophosphate - analogs & derivatives Adenosine Monophosphate - therapeutic use Alanine - analogs & derivatives Alanine - therapeutic use Amides - therapeutic use Antiviral agents Antiviral Agents - therapeutic use Betacoronavirus - drug effects Betacoronavirus - genetics Betacoronavirus - pathogenicity China China - epidemiology Chloroquine - analogs & derivatives Chloroquine - therapeutic use clinical trial Clinical trials Clinical Trials as Topic Coronaviridae Coronavirus Infections - diagnosis Coronavirus Infections - drug therapy Coronavirus Infections - epidemiology Coronavirus Infections - virology Coronaviruses COVID-19 Disease Management Disease Outbreaks Drugs Drugs, Chinese Herbal - therapeutic use Glucocorticoids Herbal medicine Humans Medicine, Chinese Traditional - methods new coronavirus pneumonia new drugs Nucleic acids Pandemics Pneumonia, Viral - diagnosis Pneumonia, Viral - drug therapy Pneumonia, Viral - epidemiology Pneumonia, Viral - virology Practice Guidelines as Topic Pyrazines - therapeutic use SARS-CoV-2 Vaccines Viral diseases Virology Viruses |
| title | Clinical trial analysis of 2019‐nCoV therapy registered in China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T14%3A29%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20trial%20analysis%20of%202019%E2%80%90nCoV%20therapy%20registered%20in%20China&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Zhang,%20Qi&rft.date=2020-06&rft.volume=92&rft.issue=6&rft.spage=540&rft.epage=545&rft.pages=540-545&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.25733&rft_dat=%3Cproquest_pubme%3E2391283955%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2391283955&rft_id=info:pmid/32108352&rfr_iscdi=true |